← Eichor
Condition: Adverse Drug Reaction Adr Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Adverse Drug Reaction Adr

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)
Phase 3 · 1 location(s) · University of Texas Southwestern Medical Center · NCT05358535
Pharmacogenetics of Antidepressant-Induced Disinhibition
Phase N/A · 1 location(s) · University of Calgary · NCT03953014
Carotid Artery Corrected Flow Time and Inferior Vena Cava Collapsibility Index for Prediction of Hypotension After Induc
Phase N/A · 1 location(s) · Tanta University · NCT06814054
Incidence of Residual Neuromuscular Blockade in Fraility in OncoGynae Surgery
NA · 1 location(s) · Mahidol University · NCT06216002
Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome
Phase N/A · 11 location(s) · University Hospital, Lille · NCT04330118
The Efficacy of Vosevi in Treating DAA-experienced Patients
Phase N/A · 1 location(s) · The Third Affiliated Hospital of Guangzhou Medical Universit · NCT06180590
Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation
Phase N/A · 2 location(s) · University of Manitoba · NCT06763081
Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery
NA · 1 location(s) · University of Ioannina · NCT07164300
Pharmacogenomics-Supported Psychotropic Prescribing Trial
NA · 2 location(s) · University of Manitoba · NCT06929533
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
Phase N/A · 2 location(s) · University of British Columbia · NCT04249375
Effect of Tegileridine Versus Sufentanil as Analgesic Components on Opioid-Induced Cough During Anesthesia Induction
NA · 1 location(s) · The First People's Hospital of Lianyungang · NCT07323043
PRE-EMPTIVE PHARMACOGENOMICS IN ACUTE CARE SETTINGS WITH HEALTH ECONOMIC EVALUATIONS (PHOENIX TRIAL)
NA · 5 location(s) · NHS Greater Glasgow and Clyde · NCT06907784
IPGx PILOT Whole Genome Sequencing Extension Cohort
Phase N/A · 1 location(s) · Texas A&M University · NCT06766071
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT01994057
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
Phase N/A · 1 location(s) · University of British Columbia · NCT00414115
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) Durin
Phase 4 · 1 location(s) · Marco Schiuma · NCT07477119
The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
NA · 1 location(s) · 4th Military Clinical Hospital with Polyclinic, Poland · NCT06707532
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
Phase N/A · 3 location(s) · Universidade do Porto · NCT06498167
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
Phase N/A · 1 location(s) · Texas A&M University · NCT06726590
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT03659227
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT04154553
The Texas Interprofessional Pharmacogenomics (IPGx)
Phase N/A · 1 location(s) · Texas A&M University · NCT06219720
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.